Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BTCY after the HOD @ $1.34.. Now Price $0.91 -0.27 (-22.88%) Volume(Heavy Day) 263,422.. Avg Vol (10-day)110.2K..
$SPDL $0.0008 -0.0002 (-20.00%) Volume 3,720,196
Big pharma one day will buyout companies like $USRM..
$BTCY.. Strong Accumulation taken place..
$BTCY $1.30 +0.12 (10.17%) Volume 144,549.. @ 9:40.. Avg Vol (10-day)110.2K
$BTCY has little recognition. Needs more exposure to lure new shareholders.
$BTCY was up 48% Friday. Way undervalued here..
I agree with your sentiments regarding the article.. $USRM is under a SEC investigation and looking for case information is difficult.
OTC Markets also added a shell risk flag. The shell risk designation indicates that a company may be a Shell Company, as defined by SEC rules. This designation is made at OTC Markets’ discretion based on an analysis of the company’s key financial data.
https://pubcoceo.com/2018/03/30/otc-markets-group-launches-new-stock-promotion-shell-risk-flags/
$USRM Insider Activity (SEC Form 4)
https://www.nasdaq.com/symbol/usrm/insider-trades
https://www.marketwatch.com/investing/stock/usrm/insideractions
Clinic biz US Stem (USRM) may be kaput in matter of weeks
https://ipscell.com/2019/03/clinic-biz-us-stem-usrm-may-be-kaput-in-matter-of-weeks/
It's a Shell Risk.. $SPDL
https://www.otcmarkets.com/stock/SPDL/overview
Stakeholders' article.. This will be much higher than a $3-4 stock. Thanks for sharing..
$BTCY is a BUY
https://www.tradingview.com/symbols/OTC-BTCY/
Impressive day.. Notes are done for now. $BTCY
Thanks for the info.. Very interesting.. $USRM
Thank you.. The public has a right to know.. $USRM
Can you post a link.. Thanks
$BTCY $1.22 +0.42 (52.50%) Volume 129,553 10:59am ET
No news until 10-K is filed on or before April 15th.. $SPDL
$BTCY $0.888 +0.088 (11.00%)
Biolife will also be a future winner when released.
Biolife will give you information on your ECG, respiration, physical activity, calorie burn, core body temperature, and more all in an easy-to-understand format. Used in a manner consistent with your doctor’s lifestyle recommendations, this knowledge will help guide your efforts to manage your heart condition and improve the quality of your life. Biolife is your portable “medical team” that helps you stay on track daily, and be at your best.
Managing a long-term chronic illness is never easy. The challenges range from fighting decades-long lifestyle habits, lack of support, and lack of evidence-based progress-feedback to keep you going on your lifelong battle for a quality life. Biolife will give you all the tools you need to succeed—and it’s easy to use.
Biolife is a must-have for anyone who is at risk for CVD because of family history, obesity, diabetes or stress—or anyone who already has heart issues. Biolife is in its development stages and will be available in the market in the near future.
https://www.biotricity.com/biolife/
$BTCY
Biotricity seeks to facilitate the development of future medical devices that are easy to utilize in either the physician’s office or the patient’s home as well as in acute-care settings. These medical-grade wearables are comfortable and small, and can offer precise remote data collection and more responsive care.
https://www.otcmarkets.com/stock/BTCY/news/Biotricity-Achieves-Significant-Milestones-for-Both-FetalMaternal-and-Ambulatory-Wellness-Monitoring-Systems?id=220498
$BTCY ready to move..
https://www.tradingview.com/symbols/OTC-BTCY/
$BTCY $0.80 +0.03 (3.90%) Volume 68,216 (Average)
Biotricity Inc lies in the lower part of a very wide and strong rising trend in the short term, and this will normally pose a very good buying opportunity. A break down the bottom trend line at $0.75 will firstly indicate a slower raising rate, but may also be a early warning for a trend shift. Given the current short-term trend, the stock is expected to rise ?23.06% during the next 3 months and, with 90% probability hold a price between $0.92 and $2.38 at the end of this period.
https://stockinvest.us/technical-analysis/BTCY
$BTCY fell by -1.91% in the last day from $0.79 to $0.77 and has now fallen 4 days in a row. The price has fallen in 8 of the last 10 days and is down by -24.51% for this period. Volume fell in the last day along with the stock, which is actually a good sign as volume should follow the stock. In the last day the trading volume fell by -38 352 shares and in total 29,303 shares bought and sold for approximately $22,563.30.
https://stockinvest.us/technical-analysis/BTCY
Nice consolidation today.. $USRM
It's already been updated in the I-Box. Each Mod can post (1) stickie note. If the mod is not on this board anymore his stickie stays and can not be deleted by another mod. $SPDL
Unrestricted shares NOT AVAILABLE.. The unrestricted share count which indicates how many tradable shares are available from the OS is not posted. Need to contact the Transfer Agent (VStock Transfer LLC) to find the amount. $CELZ
VStock Transfer LLC
Transfer Agent
18 Lafayette Place
Woodmere, NY 11598
212-828-8436
www.vstocktransfer.com
$CLSK $3.42 -0.589 (-14.71%)
$USRM has a bright future.
$USRM $0.0297 -0.0003 (-0.84%)
$USRM Authorized Shares 2,000,000,000 03/05/2019
Outstanding Shares 386,675,905 03/05/2019
Restricted 73,684,165 03/05/2019
Unrestricted 312,991,740 03/05/2019
https://www.otcmarkets.com/stock/USRM/security
SG&A (alternately SGA, SAG or SGNA) is an initialism used in accounting to refer to Selling, General and Administrative Expenses, which is a major non-production cost presented in an income statement (statement of profit or loss). $SFAD is right were they need to be and (D)ilution is very low compared to most OTC stocks.
"NEWS" Biotricity Achieves Significant Milestones for Both Fetal/Maternal and Ambulatory Wellness Monitoring Systems
7:59 am ET March 6, 2019 (Globe Newswire) Print
Biotricity, Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced that it has achieved significant progress in their University of Calgary-based R & D program for their latest wellness monitoring systems. Clinical data collection has commenced for both its fetal/maternal and ambulatory adult heart rate variability (HRV) monitoring systems.
Dr. David Liepert, QA/QI and Safety Lead and Director for the University of Calgary Cumming School of Medicine Department of Anesthesia commented, "We could not be more excited to participate in developing both these non-invasive medical-grade ambulatory monitors, utilizing the amazing fidelity and mobility of the Bioflux system. We expect both tools to contribute to better outcomes, lower costs and increased patient satisfaction."
Appropriate pre-rehabilitation and post-surgical rehabilitation has been shown to save up to $2,000 per patient and per surgery. Today, 89 percent of laboring patients in North America currently receive electronic fetal monitoring using either lower fidelity and less precise sound-based electrodes or higher fidelity fetal scalp electrodes. Trans-vaginal intrauterine pressure monitoring is used in approximately 15 percent of deliveries. Both electrode monitoring and trans-vaginal intrauterine pressure monitoring are invasive techniques that introduce possible trauma, infection, and patient discomfort.
Real-world ambulatory HRV monitoring will facilitate early risk stratification and more responsive patient management. Improved maternal/fetal prenatal and in-labor monitoring will assist caregivers to better control existing maternal conditions such as high blood pressure, diabetes and serious complications like pre-eclampsia. HRV monitoring will also facilitate safer and more comfortable antepartum care, making unforeseeable risks more predictable, manageable and potentially preventable. The U of C/Biotricity program will use actual clinical data to guide the development of efficient data processing and effective displays for both ambulatory adult medical and surgical patients and for non-invasive fetal/maternal prenatal and labor monitoring systems.
Biotricity seeks to facilitate the development of future medical devices that are easy to utilize in either the physician's office or the patient's home as well as in acute-care settings. These medical-grade wearables are comfortable and small, and can offer precise remote data collection and more responsive care.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity's R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts
McCoin & Smith Communications Inc.
Chris McCoin,
Chris@mccoinsmith.com, 508-429-5988
Richard Smith,
rick@mccoinsmith.com, 978-433-3304
Investor Relations:
Biotricity Inc.
1-800-951-3348
investors@biotricity.com
https://resource.globenewswire.com/media/b10069fc-1e26-4ada-910f-1cefcf7126ae/small/biotricity-jpg.jpg
We have established a research partnership with the University of Calgary to determine the predictive value of electrocardiogram (ECG) readings in preventative healthcare applications. The study is designed to identify novel patterns in ECG readings that may be translated into probability models for use in the development of proprietary algorithms for diagnostic applications, and to determine if ECG readings have predictive value for use in preventative healthcare applications, such as self-managed care. The research is partly funded by the National Research Council of Canada. As part of the collaboration, we have the right to license any intellectual property discovered, created or reduced to practice in the performance of the collaboration that was created solely by the University’s personnel. Otherwise, we own all intellectual property resulting from the collaboration. The term of the collaboration is until December 31, 2020.
Feel free to send $USRM a message!
http://us-stemcell.com/contact/
$USRM
Very reasonable it is.. $SPDL working diligently to keep the company moving forward.. GLTY